<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816660</url>
  </required_header>
  <id_info>
    <org_study_id>070701</org_study_id>
    <nct_id>NCT00816660</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease</brief_title>
  <official_title>Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the immediate tolerability and safety of&#xD;
      rVWF:rFVIII in subjects with Type 3 Von Willebrand Disease after administration of various&#xD;
      dosages of VWF:RCo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2008</start_date>
  <completion_date type="Actual">August 31, 2010</completion_date>
  <primary_completion_date type="Actual">August 31, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses</measure>
    <time_frame>Up to 30 days after the last investigational product infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)</intervention_name>
    <description>Single dose, dose escalation, various cohorts</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Marketed plasma-derived VWF/FVIII concentrate</intervention_name>
    <description>Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has voluntarily given written informed consent (before conduct of any&#xD;
             study-related procedures)&#xD;
&#xD;
          -  The subject has hereditary type 3 VWD (&lt;= 3 IU/dL VWF:Ag)or severe type 1 or type 2A&#xD;
             VWD (VWF:RCo &lt;= 10% and FVIII:C &lt;20%)&#xD;
&#xD;
          -  The subject has a medical history of at least 25 exposure days to VWF/FVIII&#xD;
             coagulation factor concentrates&#xD;
&#xD;
          -  The subject has a Karnofsky score &gt;= 70%&#xD;
&#xD;
          -  The subject is between 18 to 60 years of age (on the day of signing the informed&#xD;
             consent)&#xD;
&#xD;
          -  NOT APPLICABLE IN ITALY: Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test and agree to practice contraception using a method of proven&#xD;
             reliability from the day of screening until the study completion visit&#xD;
&#xD;
          -  APPLICABLE ONLY IN ITALY: Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test and agree to practice non-hormonal-based contraception using a&#xD;
             method of proven reliability (IUD acceptable) from the day of screening until 96 hours&#xD;
             after the last investigational drug infusion&#xD;
&#xD;
          -  NOT APPLICABLE IN ITALY: The subject must agree not to be on any therapy&#xD;
             (hormone-based contraception acceptable) interfering with coagulation factor&#xD;
             pharmacokinetics until 96 hours after the last investigational drug infusion&#xD;
&#xD;
          -  APPLICABLE ONLY IN ITALY: The subject must agree not to be on any therapy interfering&#xD;
             with coagulation factor pharmacokinetics until 96 hours after the last investigational&#xD;
             drug infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has been diagnosed with a hereditary or acquired coagulation disorder&#xD;
             other than VWD (including qualitative and quantitative platelet disorders and/or an&#xD;
             international normalized ratio (INR) &gt; 1.4)&#xD;
&#xD;
          -  The subject has been diagnosed with an ADAMTS13 deficiency with less than 10% ADAMTS13&#xD;
             activity&#xD;
&#xD;
          -  The subject has a history or presence of VWF inhibitor&#xD;
&#xD;
          -  The subject has a history or presence of FVIII inhibitor with a titer &gt;= 0.4 BU (by&#xD;
             Nijmegen assay) or &gt;= 0.6 BU (by Bethesda assay)&#xD;
&#xD;
          -  The subject has a known hypersensitivity to mouse or hamster proteins&#xD;
&#xD;
          -  The subject has a medical history of immunological disorders, excluding seasonal&#xD;
             allergic rhinitis/conjunctivitis, food allergies or animal allergies&#xD;
&#xD;
          -  The subject has a medical history of a thromboembolic event&#xD;
&#xD;
          -  The subject is HIV positive with an absolute CD4 count &lt; 200/mm3&#xD;
&#xD;
          -  The subject has been diagnosed with cardiovascular disease (New York Heart Association&#xD;
             (NYHA) classes 1-4)&#xD;
&#xD;
          -  The subject has been diagnosed with insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  The subject has an acute illness (e.g. influenza, flu-like syndrome, allergic&#xD;
             rhinitis/conjunctivitis)&#xD;
&#xD;
          -  The subject has been diagnosed with liver disease, as evidenced by, but not limited&#xD;
             to, any of the following: serum ALT three times the upper limit of normal,&#xD;
             hypoalbuminemia, portal vein hypertension (e.g. presence of otherwise unexplained&#xD;
             splenomegaly, history of esophageal varices)&#xD;
&#xD;
          -  The subject has been diagnosed with renal disease, with a serum creatinine level &gt;= 2&#xD;
             mg/dL&#xD;
&#xD;
          -  In the judgment of the investigator, the subject has another clinically significant&#xD;
             concomitant disease (e.g. uncontrolled hypertension, diabetes type II) that may pose&#xD;
             additional risks for the subject&#xD;
&#xD;
          -  The subject has been treated with an immunomodulatory drug, excluding topical&#xD;
             treatment (e.g. ointments, nasal sprays) within 30 days before enrollment&#xD;
&#xD;
          -  The subject has been treated with drugs known to induce thrombotic thrombocytopenic&#xD;
             purpura (TTP) (e.g. Adenosine diphosphate (ADP) receptor inhibitors (Clopidogrel,&#xD;
             Ticlopidine)) within 60 days before enrollment&#xD;
&#xD;
          -  The subject is receiving or anticipates receiving another investigational and/or&#xD;
             interventional drug within 30 days before enrollment&#xD;
&#xD;
          -  The subject is a lactating female&#xD;
&#xD;
          -  The subject has a history of drug or alcohol abuse within the last 5 years&#xD;
&#xD;
          -  The subject has a progressive fatal disease and/or life expectancy of less than 3&#xD;
             months&#xD;
&#xD;
          -  The subject is identified by the investigator as being unable or unwilling to&#xD;
             cooperate with study procedures&#xD;
&#xD;
          -  The subject suffers from a mental condition rendering him/her unable to understand the&#xD;
             nature, scope and possible consequences of the study and/or evidence of an&#xD;
             uncooperative attitude&#xD;
&#xD;
          -  Subject is in prison or compulsory detention by regulatory and/or juridical order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine, Dept. of Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hemophilia Treatment Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women´s Hospital, Hematology Division</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemophilia Center of Western PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-4306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center for Bleeding Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53225-3548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Vienna (Allgemeines Krankenhaus der Stadt Wien), University Department for Internal Medicine I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q.E.II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2YP</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School - Clinic for Haematology, Haemostaseology, Oncology and Stem Cell Transplantation</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Thrombophilie und Hämostaseologie</name>
      <address>
        <city>Münster</city>
        <zip>48143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-universitaria &quot;Careggi&quot;</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giannia Gaslini Children´s Hospital</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore di Milano, Centro Emofilia e Trombosi &quot;Angelo Bianchi Bonomi&quot;</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco, Centro Emofilia Divisione di Ematologia</name>
      <address>
        <city>Naples</city>
        <zip>80144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padua Medical School</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Vicenza - U.L.S.S.N.6</name>
      <address>
        <city>Vicenza</city>
        <zip>80144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Midlands Region Adult Haemophilia Centre, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College School of Medicine, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester Healthcare NHS Trust, Manchester Haemophilia Comprehensive Care Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2009</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
    <mesh_term>Von Willebrand Disease, Type 3</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

